# Prostate Cancer Biomarker Enrichment and Treatment Selection

Source: https://onco.cc/trials/nct03385655/  
OnCo record `nct03385655` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CFI-400945 run by Canadian Cancer Trials Group, active and no longer recruiting.

## Summary

Prostate Cancer Biomarker Enrichment and Treatment Selection is a phase 2 interventional study registered as NCT03385655 by Canadian Cancer Trials Group, with 200 participants planned, started 2018-08-01. Conditions recorded: Prostate Cancer. Interventions recorded: Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab and Carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03385655
- Phase: 2
- Setting: Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
- Sponsor: Canadian Cancer Trials Group
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT03385655: https://clinicaltrials.gov/study/NCT03385655

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [CFI-400945](https://onco.cc/drugs/cfi-400945/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03385655.json